H.C. Wainwright reiterates Buy rating on Microbot Medical stock at $12
PositiveFinancial Markets

H.C. Wainwright has reaffirmed its Buy rating on Microbot Medical stock, setting a price target of $12. This endorsement is significant as it reflects confidence in the company's potential for growth and innovation in the medical technology sector. Investors may find this an encouraging sign, suggesting that Microbot Medical is well-positioned for future success.
— Curated by the World Pulse Now AI Editorial System